Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of PF614 and BA/BE vs OxyContin
NCT05043766Phase 1Completed
- Sponsor
- Ensysce Biosciences
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF614 in pain (2 arms), sponsored by Ensysce Biosciences. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 30 days, Pharmacokinetics Area Under the Curve at 12 hours and 8 more. Started Sep 2021; status: completed.
02
Drugs
PF614
03
Conditions
pain
Beyond the preview
Go deeper on NCT05043766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043766.